α7 Nicotinic Acetylcholine Receptor as a Therapeutic Target in Central Nervous System Diseases: Prospects and Limitations.

INTRODUCTION

The α7 nicotinic acetylcholine receptor (α7nAChR), a transmitter-gated ion channel, is normally activated by the endogenous neurotransmitter acetylcholine (ACh). Its activation triggers a distinctive cholinergic anti-inflammatory pathway, leading to anti-inflammatory effects in the central nervous system (CNS). This unique pharmacological property has positioned α7nAChR as a promising therapeutic target for multiple CNS disorders. This review delineates α7nAChR's multifaceted roles in CNS pathophysiology, appraises current clinical trial progress of its modulators, and elucidates key challenges and future directions for the development of next-generation therapeutics targeting α7nAChR.

METHODS

Studies demonstrate that activation of α7nAChR represents a promising therapeutic strategy for diverse CNS disorders, including neurodegenerative, cerebrovascular, and neurodevelopmental diseases.

RESULTS

Studies demonstrate that activation of the α7nAChR is a promising therapeutic strategy for diverse CNS diseases, including neurodegenerative, cerebrovascular, and neurodevelopmental diseases.

DISCUSSION: This review highlights the core therapeutic value of α7nAChR in CNS disorders while identifying bottlenecks in its research and development. On one hand, preclinical studies show that α7nAChR's anti-inflammatory and neuroprotective effects support its potential as a therapeutic target. On the other hand, clinical trial data-including limited efficacy and dose-limiting cardiovascular adverse effects-reveal a persistent translational gap from preclinical to clinical.

CONCLUSION

Although α7nAChR agonists hold considerable therapeutic potential, substantial challenges remain in clinical translation. Major hurdles include: (1) the inherent complexity of the CNS microenvironment, which affects receptor pharmacology; (2) insufficient subtype selectivity, leading to off-target effects; and (3) a scarcity of clinically efficacious compounds. Addressing these limitations is crucial for the successful development of α7nAChR-targeted therapies.